Cancer Research AACR Membership  Telomeres
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Yang, J.
Right arrow Articles by Navone, N. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Yang, J.
Right arrow Articles by Navone, N. M.
[Cancer Research 61, 5652-5659, July 15, 2001]
© 2001 American Association for Cancer Research


Tumor Biology

Prostate Cancer Cells Induce Osteoblast Differentiation through a Cbfa1-dependent Pathway1

Jun Yang2, Karim Fizazi2, Sara Peleg, Charles R. Sikes, A. Kevin Raymond, Nausheen Jamal, Min Hu, Matilde Olive, Luis A. Martinez, Christopher G. Wood, Christopher J. Logothetis, Gerard Karsenty and Nora M. Navone3

Department of Genitourinary Medical Oncology [J. Y., K. F., C. R. S., M. O., L. A. M., C. J. L., N. M. N.], Pathology [A. K. R.], Urology [C. G. W.], and Endocrine Neoplasia and Hormonal Disorders [S. P., N. J., M. H.], The University of Texas M. D. Anderson Cancer Center, and Department of Molecular and Human Genetics Baylor College of Medicine [G. K.], Houston, Texas 77030

Metastases from prostatic adenocarcinoma (prostate cancer) are characterized by their predilection for bone and typical osteoblastic features. An in vitro model of bone metastases from prostate cancer was developed using a bicompartment coculture system of mouse osteoblasts and human prostate cancer cells. In this model, the bone-derived prostate cancer cell lines MDA PCa 2a and MDA PCa 2b induced a specific and reproducible increase in osteoblast proliferation. Moreover, these cells were able to induce osteoblast differentiation, as assessed by increased alkaline phosphatase activity, Osteocalcin expression, and calcified matrix formation. This osteoblastic reaction was confirmed in vivo by intrafemoral injection of MDA PCa 2b cells into severe combined immunodeficiency disease mice. In contrast, the highly undifferentiated, bone-derived human prostate cancer cell line PC3 did not produce an osteoblastic reaction in vitro and induced osteolytic lesions in vivo. The osteoblast differentiation induced by MDA PCa 2b cells was associated with up-regulation of the osteoblast-specific transcriptor factor Cbfa1. Moreover, treatment of osteoblasts with conditioned medium obtained from MDA PCa 2b cells resulted in up-regulation of Cbfa1 and Osteocalcin expression. In support of the differentiation studies, a microarray analysis showed that primary mouse osteoblasts grown in the presence of MDA PCa 2b cells showed a shift in the pattern of gene expression with an increase in mRNA-encoding Procollagen type I and Osteopontin and a decrease in mRNA-encoding proteins associated with myoblast differentiation, namely myoglobin and myosin light-chain 2. Taken together, these findings suggest that the bone-derived prostate cancer cells MDA PCa 2a and MDA PCa 2b promote differentiation of osteoblast precursors to an osteoblastic phenotype through a Cbfa1-dependent pathway. These results also established that soluble factors produced by prostate cancer cells can induce expression of osteoblast-specific genes. This in vitro model provides a valuable system to isolate molecules secreted by prostate cancer cells that favor osteoblast differentiation. Moreover, it allows to screen for therapeutic agents blocking the osteoblast response to prostate cancer.




This article has been cited by other articles:


Home page
Anticancer ResHome page
H. KATOPODIS, A. PHILIPPOU, R. TENTA, C. DOILLON, K. K. PAPACHRONI, A. G. PAPAVASSILIOU, and M. KOUTSILIERIS
MG-63 Osteoblast-like Cells Enhance the Osteoprotegerin Expression of PC-3 Prostate Cancer Cells
Anticancer Res, October 1, 2009; 29(10): 4013 - 4018.
[Abstract] [Full Text] [PDF]


Home page
Mol Cancer ResHome page
Y. Jung, Y. Shiozawa, J. Wang, J. Wang, Z. Wang, E. A. Pedersen, C. H. Lee, C. L. Hall, P. J. Hogg, P. H. Krebsbach, et al.
Expression of PGK1 by Prostate Cancer Cells Induces Bone Formation
Mol. Cancer Res., October 1, 2009; 7(10): 1595 - 1604.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
K. Fizazi, P. Beuzeboc, J. Lumbroso, V. Haddad, C. Massard, M. Gross-Goupil, M. Di Palma, B. Escudier, C. Theodore, Y. Loriot, et al.
Phase II Trial of Consolidation Docetaxel and Samarium-153 in Patients With Bone Metastases From Castration-Resistant Prostate Cancer
J. Clin. Oncol., May 20, 2009; 27(15): 2429 - 2435.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
K. Fizazi, A. Lipton, X. Mariette, J.-J. Body, Y. Rahim, J. R. Gralow, G. Gao, L. Wu, W. Sohn, and S. Jun
Randomized Phase II Trial of Denosumab in Patients With Bone Metastases From Prostate Cancer, Breast Cancer, or Other Neoplasms After Intravenous Bisphosphonates
J. Clin. Oncol., April 1, 2009; 27(10): 1564 - 1571.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
S.-H. Lin, Y.-C. Lee, M. B. Choueiri, S. Wen, P. Mathew, X. Ye, K.-A. Do, N. M. Navone, J. Kim, S.-M. Tu, et al.
Soluble ErbB3 Levels in Bone Marrow and Plasma of Men with Prostate Cancer
Clin. Cancer Res., June 15, 2008; 14(12): 3729 - 3736.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
V. Lamour, C. Detry, C. Sanchez, Y. Henrotin, V. Castronovo, and A. Bellahcene
Runx2- and Histone Deacetylase 3-mediated Repression Is Relieved in Differentiating Human Osteoblast Cells to Allow High Bone Sialoprotein Expression
J. Biol. Chem., December 14, 2007; 282(50): 36240 - 36249.
[Abstract] [Full Text] [PDF]


Home page
Ann OncolHome page
K. Fizazi
The role of Src in prostate cancer
Ann. Onc., November 1, 2007; 18(11): 1765 - 1773.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
N. Chen, X.-C. Ye, K. Chu, N. M. Navone, E. H. Sage, L.-Y. Yu-Lee, C. J. Logothetis, and S.-H. Lin
A Secreted Isoform of ErbB3 Promotes Osteonectin Expression in Bone and Enhances the Invasiveness of Prostate Cancer Cells
Cancer Res., July 15, 2007; 67(14): 6544 - 6548.
[Abstract] [Full Text] [PDF]


Home page
Mol Cancer ResHome page
C.-J. Cheng, X.-c. Ye, F. Vakar-Lopez, J. Kim, S.-M. Tu, D.-T. Chen, N. M. Navone, L.-Y. Yu-Lee, S.-H. Lin, and M. C-T. Hu
Bone Microenvironment and Androgen Status Modulate Subcellular Localization of ErbB3 in Prostate Cancer Cells
Mol. Cancer Res., July 1, 2007; 5(7): 675 - 684.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
X.-H. Liu, A. Kirschenbaum, S. Yao, G. Liu, S. A. Aaronson, and A. C. Levine
Androgen-Induced Wnt Signaling in Preosteoblasts Promotes the Growth of MDA-PCa-2b Human Prostate Cancer Cells
Cancer Res., June 15, 2007; 67(12): 5747 - 5753.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
K. A. Mohamedali, A. T. Poblenz, C. R. Sikes, N. M. Navone, P. E. Thorpe, B. G. Darnay, and M. G. Rosenblum
Inhibition of Prostate Tumor Growth and Bone Remodeling by the Vascular Targeting Agent VEGF121/rGel.
Cancer Res., November 15, 2006; 66(22): 10919 - 10928.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
M. Qiao, P. Shapiro, M. Fosbrink, H. Rus, R. Kumar, and A. Passaniti
Cell Cycle-dependent Phosphorylation of the RUNX2 Transcription Factor by cdc2 Regulates Endothelial Cell Proliferation
J. Biol. Chem., March 17, 2006; 281(11): 7118 - 7128.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
N. Nadiminty, W. Lou, S. O. Lee, F. Mehraein-Ghomi, J. S. Kirk, J. M. Conroy, H. Zhang, and A. C. Gao
Prostate-Specific Antigen Modulates Genes Involved in Bone Remodeling and Induces Osteoblast Differentiation of Human Osteosarcoma Cell Line SaOS-2
Clin. Cancer Res., March 1, 2006; 12(5): 1420 - 1430.
[Abstract] [Full Text] [PDF]


Home page
Mol. Cell. Biol.Home page
J. Pratap, A. Javed, L. R. Languino, A. J. van Wijnen, J. L. Stein, G. S. Stein, and J. B. Lian
The Runx2 Osteogenic Transcription Factor Regulates Matrix Metalloproteinase 9 in Bone Metastatic Cancer Cells and Controls Cell Invasion
Mol. Cell. Biol., October 1, 2005; 25(19): 8581 - 8591.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
S. Miwa, A. Mizokami, E. T. Keller, R. Taichman, J. Zhang, and M. Namiki
The Bisphosphonate YM529 Inhibits Osteolytic and Osteoblastic Changes and CXCR-4-Induced Invasion in Prostate Cancer
Cancer Res., October 1, 2005; 65(19): 8818 - 8825.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
M. Goya, S. Miyamoto, K. Nagai, Y. Ohki, K. Nakamura, K. Shitara, H. Maeda, T. Sangai, K. Kodama, Y. Endoh, et al.
Growth Inhibition of Human Prostate Cancer Cells in Human Adult Bone Implanted into Nonobese Diabetic/Severe Combined Immunodeficient Mice by a Ligand-Specific Antibody to Human Insulin-Like Growth Factors
Cancer Res., September 1, 2004; 64(17): 6252 - 6258.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
K. Fizazi, J. Yang, S. Peleg, C. R. Sikes, E. L. Kreimann, D. Daliani, M. Olive, K. A. Raymond, T. J. Janus, C. J. Logothetis, et al.
Prostate Cancer Cells-Osteoblast Interaction Shifts Expression of Growth/Survival-related Genes in Prostate Cancer and Reduces Expression of Osteoprotegerin in Osteoblasts
Clin. Cancer Res., July 1, 2003; 9(7): 2587 - 2597.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
Y. Sohara, H. Shimada, M. Scadeng, H. Pollack, S. Yamada, W. Ye, C. P. Reynolds, and Y. A. DeClerck
Lytic Bone Lesions in Human Neuroblastoma Xenograft Involve Osteoclast Recruitment and Are Inhibited by Bisphosphonate
Cancer Res., June 15, 2003; 63(12): 3026 - 3031.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
J. Kim, W. Luo, D.-T. Chen, K. Earley, J. Tunstead, L.-Y. Yu-Lee, and S.-H. Lin
Antitumor Activity of the 16-kDa Prolactin Fragment in Prostate Cancer
Cancer Res., January 15, 2003; 63(2): 386 - 393.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
S. Mohr, G. D. Leikauf, G. Keith, and B. H. Rihn
Microarrays as Cancer Keys: An Array of Possibilities
J. Clin. Oncol., July 15, 2002; 20(14): 3165 - 3175.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2001 by the American Association for Cancer Research.